CARLSBAD, Calif., Sept. 8, 2011 /PRNewswire/ — Isis
Pharmaceuticals, Inc. (Nasdaq:
ISIS) announces the following webcast:What:
Data from Mipomersen’s Open-Label Extension Study presented at
Monday, September 12, 2011 at 12:00 p.m. ET / 9:00 a.m.
Live on the Internet. Simply log onto our Web site listed
above. If you are unable to participate during the live event, a
replay of the webcast will be available for a limited time at www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its
leadership position in antisense technology to discover and develop
novel drugs for its product pipeline and for its partners.
Isis’ broad pipeline consists of 24 drugs to treat a wide
variety of diseases with an emphasis on cardiovascular, metabolic
and severe and rare/neurodegenerative diseases, and cancer.
Isis’ partner, Genzyme, plans to commercialize Isis’ lead
product, mipomersen following regulatory approval, which is
expected in 2012. Isis’ patents provide strong and extensive
protection for its drugs and technology. Additional
information about Isis is available at www.isispharm.com.